 This is an open-label, single arm study evaluating a multi-peptide tumor-associated antigensMontanide vaccine in patients 21 years of age with recurrent or refractory CNS tumors. The study primarily evaluates the safety of this regimen. Secondarily, immunogenicity and anti-tumor effects will be assessed. 